99Tc-MDP联合MTX、艾拉莫德治疗类风湿关节炎的临床分析
2020-12-23刘莎朱辉冯乐恒宋丽萍李荣滨许雪莲宫笑微刘微杨晶
刘莎 朱辉 冯乐恒 宋丽萍 李荣滨 许雪莲 宫笑微 刘微 杨晶


[摘要] 目的 对类风湿关节炎患者予以99Tc-MDP联合MTX、艾拉莫德治疗,探索最佳治疗措施。方法 便利选择该院2019年1—6月收治的60例RA患者,采用随机信封分配病例将所有患者分为观察组及对照组,各30例。T0、T1、T2、T3采血检测ESR、CRP、RF水平以及观察安全性,观察患者疼痛改善情况。结果 在T2时间段,与对照组比较,观察组的ESR(31.2±5.6)mm/h、CRP(13.5±3.1)mg/L、RF(56.7±6.1)U/mL以及VAS(5.2±0.6)分、DAS28(4.2±0.8)分,得分均降低明显,差异有统计学意义(t=4.289、5.267、9.256、4.156、3.519,P<0.05);T3时间段,两组差异有统计学意义(t=7.891、 6.283、10.251、7.214、4.251,P<0.05)。与对照组比较,观察组的ACR20缓解比例降低,ACR50、70的缓解比例则升高明显,差异有统计学意义(χ2=11.257、10.892、5.438,P<0.05)。在T3时间段,观察组的不良反应6例(20.00%),对照组不良反应5例(16.67%),两组比较差异无统计学意义(χ2=1.210,P>0.05)。结论 99Tc-MDP联合MTX、艾拉莫德治疗类风湿关节炎12周,可有效改善患者的关节炎性指标,降低疼痛,具有较好的安全性。
[关键词] 类风湿关节炎;99Tc-MDP;MTX;艾拉莫德
[中图分类号] R593.22 [文献标识码] A [文章编号] 1674-0742(2020)06(b)-0124-03
[Abstract] Objective To treat patients with rheumatoid arthritis with 99Tc-MDP combined with MTX and ilammod, and explore the best treatment measures. Methods Sixty patients with RA admitted to the hospital from January 2019 to June 2019 were convenienty selected. All patients were divided into observation group and control group by random envelope distribution. T0, T1, T2, T3 blood collection to detect ESR, CRP, RF levels and observe safety, observe the patient's pain improvement. Results At T2, compared with the control group, the observation group had ESR (31.2±5.6)mm/h, CRP (13.5±3.1)mg/L, RF (56.7±6.1)U/mL, VAS (5.2±0.6)points, DAS28 (4.2±0.8)points, and scores decreased significantly, and the difference was statistically significant (t=4.289, 5.267, 9.256, 4.156, 3.519,P<0.05); T3 time period, the difference between the two groups increased further, with statistical significance (t=7.891, 6.283, 10.251, 7.214, 4.251,P<0.05). Compared with the control group, the remission rate of ACR20 in the observation group decreased, while the remission rate of ACR50 and 70 increased significantly, the difference was statistically significant (χ2=11.257, 10.892, 5.438; P<0.05). During the T3 period, there were 6 cases (20.00%) of adverse reactions in the observation group and 5 cases (16.67%) of the control group. There was no statistical difference between the two groups (χ2=1.210,P>0.05). Conclusion The treatment of rheumatoid arthritis with 99Tc-MDP combined with MTX and ilammod for 12 weeks can effectively improve the arthritis index of patients, reduce pain, and has good safety.
[Key words] Rheumatoid arthritis; 99Tc-MDP; MTX; Ilammod
類风湿关节炎(rheumatoid arthritis,RA) 是风湿科最常见的自身免疫性疾病,主要临床表现为对称性、侵蚀性多关节炎,可累及呼吸、循环、血液、神经等系统,其病程中逐渐出现关节软骨破坏、畸形和功能丧失等情况,严重者可影响生活质量[1]。对RA炎性因子的生物制剂、针对JAK通路的抑制剂,有较好的临床效果,但生物制剂的价格对国人来说尚属高端消费,其疗效和不良反应尚不十分明确[6]。目前针对该病的国产原研药物开发、应用较少,研究RA新的联合治疗方案,无论在发病机制上还是在治疗方法以及治疗费用上均有着重要的意义。有鉴于此,该院将自2019年1—6月收治的60例RA患者研究治疗类风湿关节炎的疗效与安全性,为类风湿关节炎临床治疗提供新思路,现报道如下。
1 对象与方法
1.1 研究对象
方便选取60例RA患者按照入组顺序,采用随机信封分配病例,随机分入观察组(99Tc-MDP+MTX+艾拉莫德治疗)30例及对照组(MTX+艾拉莫德治疗)30例。……
